Form 4: Tarsus COO Gifts Shares to Daughter
Insider Transaction Report
Tarsus Pharmaceuticals' Chief Operating Officer, Seshadri Neervannan, reported gifting 475 shares of common stock to his daughter.
Summary
- Seshadri Neervannan, Chief Operating Officer of Tarsus Pharmaceuticals, Inc., reported a transaction involving common stock.
- On December 16, 2025, Mr. Neervannan gifted 475 shares of common stock to his daughter.
- Following this transaction, Mr. Neervannan directly beneficially owns 79,183 shares of common stock.
- His daughter indirectly beneficially owns 475 shares of common stock, which were part of the gift.
- The reported direct beneficial ownership of 79,183 shares includes 451 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.
- Mr. Neervannan disclaims beneficial ownership of the securities held by his daughter for Section 16 purposes.
Sentiment
Score: 5
Explanation: The filing reports a gift of shares by an insider, which is a neutral event regarding the company's operational performance or financial health. It does not indicate a change in management's confidence or company prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Management Comments
- The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Industry Context
This insider transaction report (Form 4) details a personal stock transfer by an executive and does not provide information related to broader industry trends or competitive landscape.
Related Party Transactions
- Seshadri Neervannan gifted 475 shares of Tarsus Pharmaceuticals, Inc. common stock to his daughter, who shares his household.
Stakeholder Impact
- Shareholders: Minimal impact due to the small number of shares involved in a gift transaction, which does not reflect a change in market sentiment or company fundamentals.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Acquisition of 451 shares under the Issuer's Employee Stock Purchase Plan. |
| 12/16/2025 | Transaction date for the gift of common stock. |
| 12/18/2025 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Tarsus Pharmaceuticals, TARS, Seshadri Neervannan, Insider Transaction, Form 4, Common Stock, Gift
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.